Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for MSL
1.06
0.00 (0.00%)
Apr 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.02 - 1.07
52 week 0.95 - 2.20
Open 1.07
Vol / Avg. 111,200.00/161,756.00
Mkt cap 124.02M
P/E     -
Div/yield     -
EPS -0.13
Shares 117.00M
Beta 1.42
Inst. own     -
May 9, 2017
Q2 2017 Merus Labs International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 1, 2017
Merus Labs International Inc at Bloom Burton & Co. Healthcare Investor Conference - 11:00AM EDT - Add to calendar
Apr 6, 2017
Merus Labs International Inc at Laurentian Bank Securities Institutional Investor Conference
Feb 14, 2017
Q1 2017 Merus Labs International Inc Earnings Release
Feb 14, 2017
Q1 2017 Merus Labs International Inc Earnings Call
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -24.23% -10.39%
Operating margin -14.24% 0.38%
EBITD margin - 44.57%
Return on average assets -6.88% -2.96%
Return on average equity -13.14% -5.00%
Employees 13 -
CDP Score - -

Address

100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933701 (Phone)
+1-416-5934434 (Fax)

Website links

Description

Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.

Officers and directors

Michael S. Cloutier Independent Chairman of the Board
Barry Fishman Chief Executive Officer, Director
Michael Bumby Chief Financial Officer
Age: 51
Robert McLay Vice President - Sales and Marketing
Frank Rotmann Vice President and Head of European Operations
Robert Bloch M.D. Director
Theresa Sheila Firestone Independent Director
David D. Guebert CPA Independent Director
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director